Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world effectiveness of Zevorcabtagene Autoleucel (Saikeize) in relapsed/refractory multiple myeloma
CTR20241849Phase 4Active
- Sponsor
- Kaixing Life Science
- Start
- May 2024
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Countries
- 1
01
Overview
A Phase 4 trial of zevorcabtagene autoleucel in multiple myeloma (MM), sponsored by Kaixing Life Science. Started May 2024; status: active.
02
Drugs
zevorcabtagene autoleucel
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on CTR20241849.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20241849.